HC Wainwright Reaffirms Buy Rating for Entrada Therapeutics (NASDAQ:TRDA)
HC Wainwright reaffirmed their buy rating on shares of Entrada Therapeutics (NASDAQ:TRDA – Free Report) in a report issued on Monday morning,Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock. Several other equities analysts have also issued reports on the company. Roth Capital raised Entrada Therapeutics to a “strong-buy” rating in […]
HC Wainwright reaffirmed their buy rating on shares of Entrada Therapeutics (NASDAQ:TRDA – Free Report) in a report issued on Monday morning,Benzinga reports. HC Wainwright currently has a $20.00 target price on the stock. Several other equities analysts have also issued reports on the company. Roth Capital raised Entrada Therapeutics to a “strong-buy” rating in […]
